Subject 001683 was a 54-year-old Ca

受试者001683是一名54岁的白种女性，她于8/5/10接受了第一剂量的neratinib。14天后，她在工作中经历了20多次腹泻，腹痛，发汗，视力模糊以及短暂的晕厥发作。她因低血压入院（80/40）。实验室对于4级转氨酶升高（ALT为1376，AST为1757）具有重要意义，这导致了neratinib的永久停用。胆红素保持在正常范围内。她接受了静脉补液治疗。转氨酶升高被认为已于/恢复

Subject 001683 was a 54-year-old Caucasian woman who received her first dose of neratinib on 8/5/10. Fourteen days later, she experienced more than 20 episodes of diarrhea associated with abdominal pain, diaphoresis, blurry vision, and a brief syncopal episode while at work. She was admitted to the hospital with hypotension (80/40). Labs were significant for Grade 4 transaminase elevations (ALT was 1376 and AST was 1757), which led to permanent discontinuation of neratinib. Bilirubin remained within normal limits. She was treated with IV hydration. The transaminase elevations were considered recovered/resolved on ...

受试者001683是一名54岁的白人妇女，她于2010年8月5日接受了第一剂尼拉替尼。14天后，她在工作中经历了20多次腹泻，伴有腹痛、发汗、视力模糊和短暂的切分音。她因低血压入院（80/40）。实验室对4级转氨酶升高（ALT为1376，AST为1757）有显著意义，导致尼拉替尼永久停药。胆红素保持在正常范围内。她接受静脉补液治疗。转氨酶升高被认为已恢复/解决